drugset
drugset / Trial / NCT07215390

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

NCT07215390 ↗

Phase 2 Recruiting 240 enrolled Apellis Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Timeline

Start
2025-06-23
Primary completion
2027-06-25
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject APL-3007 Unknown — Subcutaneous
Background Pegcetacoplan Peptide — —

Indications

retinal degeneration